Abstract 146P
Background
This meta-analysis collected studies with propensity score matching analysis (PSM) or Randomized Controlled Trial(RCT) and focused on comparing the short-term and oncological outcomes of patients with HCC who underwent anatomic liver resection (AR) versus non-anatomic liver resection (NAR), to provide relatively high-level evidence of AR in treating patients with HCC in comparison with NAR.
Methods
A systematic literature search was performed using the PubMed, Embase, Cochrane Library and Web of Science to identify studies comparing AR with NAR by June 2019. The Newcastle-Ottawa Quality Assessment Scale (NOS) was used to evaluate the quality of the research included. The data were analyzed using Review Manager (Version 5.3). Dichotomous data were calculated by odds ratio (OR) and continuous data were calculated by weighed mean difference (WMD) with 95% confidence intervals (CI).
Results
A total of 11 studies (PSM=10; RCT=1) enrolling 2905 patients (AR = 1452; NAR=1453) with HCC were included in the present meta-analysis. For oncological outcomes, no significant differences were observed in disease-free survival (1 year: OR = 0.75, 95% CI:0.55∼1.03, P = 0.07; 3 year: OR = 0.85, 95% CI: 0.70∼1.03, P = 0.09; 5 year: OR = 0.87, 95% CI: 0.70∼1.10, P = 0.24) and overall survival (1 year: OR = 1.04, 95% CI:0.78∼1.38, P = 0.79; 3 year: OR = 0.88, 95% CI: 0.63∼1.23, P = 0.47; 5 year: OR = 0.82, 95% CI: 0.58∼1.17, P = 0.27) between the two groups. In addition, the pooled analysis suggested that no differences were found between the AR groups and NAR group with respect to operative time (WMD=17.98min, 95% CI: -2.18∼38.14, P = 0.08), blood loss (WMD=93.82ml, 95% CI: -32.68∼220.33, P = 0.15) and postoperative morbidity (OR = 0.88, 95% CI:0.57∼1.35, P = 0.55).
Conclusions
The present PSM and RCT data meta-analysis suggests that there does not appear to be a significant difference in survival between patients undergoing AR or NAR for HCC. Simultaneously, AR does not seem to bring more prognostic benefits in oncological outcomes including disease-free survival and overall survival. Considering unavoidable bias, more high-quality RCTs are badly needed to determine whether AR OR NAR can become standard practice for treating HCC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Xiujun Cai is responsible for the governance, coordination and running of the study.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
87P - Negative to positive lymph node ratio-prognostic marker of survival in node positive rectal cancer
Presenter: Pavan Jonnada
Session: Poster display session
Resources:
Abstract
88P - The Sidra LUMC advanced colon cancer NGS cohort
Presenter: Wouter Hendrickx
Session: Poster display session
Resources:
Abstract
89P - A phase II trial of adjuvant chemoradiotherapy for patients with high-risk rectal submucosal invasive cancer after local resection
Presenter: Masaaki Noguchi
Session: Poster display session
Resources:
Abstract
90P - High MICB expression confers prognostic benefit in colorectal cancer
Presenter: Shanchao Yu
Session: Poster display session
Resources:
Abstract
91P - Adjuvant therapy for high-risk stage II or stage III colon adenocarcinoma: A propensity score-matched, nationwide, population-based cohort study
Presenter: Chien-Hsin Chen
Session: Poster display session
Resources:
Abstract
92P - Prospective randomized controlled study comparing primary surgery versus neoadjuvant chemotherapy followed by surgery in gastric carcinoma
Presenter: Vipin Goel
Session: Poster display session
Resources:
Abstract
93P - Biomarker selection of liver metastatic colorectal patients for anti-EGFR monoclonal antibodies: A machine learning analysis
Presenter: Yijiao Chen
Session: Poster display session
Resources:
Abstract
94P - NORTH/HGCSG1003: North Japan multicenter phase II study of oxaliplatin-containing regimen as adjuvant chemotherapy for stage III colon cancer: Final analysis
Presenter: Michio Nakamura
Session: Poster display session
Resources:
Abstract
95P - Anatomical resections improve relapse-free survival in patients with KRAS/NRAS/BRAF- mutated colorectal liver metastases
Presenter: Ye Wei
Session: Poster display session
Resources:
Abstract
96P - Incidence, characteristics and prognosis in colorectal cancer with CNS metastases
Presenter: Nicola Taylor
Session: Poster display session
Resources:
Abstract